EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Changing Treatment Paradigm for Prolactinoma—A Prospective Series of 100 Consecutive Neurosurgical Cases

Victoria R van Trigt iD, Leontine E H Bakker, Iris C M Pelsma iD, Ingrid M Zandbergen iD, Maaia M Jentus iD, Mark C Kruit iD, Olaf M Dekkers iD, Wouter R van Furth iD, Marco J T Verstegen iD, Nienke R Biermasz iD, Dutch Prolactinoma Study Group

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Victoria R van Trigt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden, Leiden University Medical Center, Albinusdreef 2, 2333 ZA …. Hauptthemen laut MEDLINE: Prolactinoma, Pituitary Neoplasms, Neurosurgical Procedures. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate patients with prolactinoma treated surgically in a time when elective prolactinoma surgery became routine in our center, using a comprehensive outcome set, focusing on preoperative assessments, surgical outcomes, and health-related quality of life (HR-QoL).

Methods

Cohort of consecutive patients with prolactinoma undergoing surgery between January 2021 and August 2023. Clinical data were collected during multidisciplinary team meetings/from medical records at distinct timepoints: (1) presurgery, (2) 2 weeks postsurgery, (3) 6 months postsurgery, and (4) follow-up (median, 15.0 [10.0-24.8 months]). HR-QoL was measured using the Leiden Bothers and Needs Pituitary questionnaire. Data were described for all patients, and patients undergoing elective total resection, with additional subgroups of (1) patients undergoing a high-probability first total resection and (2) reoperations aiming for total resection.

Results

One hundred surgically treated patients with prolactinoma were included (72 female). Dopamine agonist intolerance was the most frequent indication (n = 68). The surgical goal (debulking/total resection) was achieved in 90% of patients. Long-term complications occurred in 4% of patients. Seventy-eight patients underwent an elective total resection, achieving remission in 91%. The subsets of preoperatively estimated high-probability-first total resections (n = 52) and reoperations (n = 9) achieved remission in 92% and 89%, respectively. Leiden Bothers and Needs Pituitary Total Bothers and Total Needs scores improved significantly after surgery (P < .001, Δ-3.4 [interquartile range, −14.4 to −0.9] and P = .006, Δ-1.8 [interquartile range, −11.9 to 1.3]), respectively.

Conclusion

High remission rates were achieved, improving HR-QoL, demonstrating (repeat) prolactinoma surgery is effective in an experienced pituitary center, as highlighted in the most recent guideline (2023).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProlactinomaPituitary NeoplasmsNeurosurgical ProceduresHumansFemaleMaleMiddle AgedQuality of LifeAdultProspective StudiesFollow-Up StudiesTreatment OutcomeYoung AdultAgedPostoperative ComplicationsElective Surgical ProceduresReoperation

Stichwörter der Autor:innen

complicationshealth-related quality of lifeprolactinomaremissiontranssphenoidal surgery

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, and Center for Endocrine Tumors Leiden, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
  • Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
  • Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
  • Department of Neurosurgery, Leiden University Medical Center, University Neurosurgical Center Holland, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.

ORCID-Profile: Victoria R van Trigt, Iris C M Pelsma, Ingrid M Zandbergen, Maaia M Jentus, Mark C Kruit, Olaf M Dekkers, Wouter R van Furth, Marco J T Verstegen, Nienke R Biermasz

Zitieren

APA

van Trigt, V. R., Bakker, L. E. H., Pelsma, I. C. M., Zandbergen, I. M., Jentus, M. M., Kruit, M. C., Dekkers, O. M., van Furth, W. R., Verstegen, M. J. T., Biermasz, N. R., & Dutch Prolactinoma Study Group (2025). The Changing Treatment Paradigm for Prolactinoma—A Prospective Series of 100 Consecutive Neurosurgical Cases. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae652

Vancouver

van Trigt VR, Bakker LEH, Pelsma ICM, Zandbergen IM, Jentus MM, Kruit MC, et al. The Changing Treatment Paradigm for Prolactinoma—A Prospective Series of 100 Consecutive Neurosurgical Cases. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae652

BibTeX
@article{vanTrigt2025,
  author = {van Trigt, Victoria R and Bakker, Leontine E H and Pelsma, Iris C M and Zandbergen, Ingrid M and Jentus, Maaia M and Kruit, Mark C and Dekkers, Olaf M and van Furth, Wouter R and Verstegen, Marco J T and Biermasz, Nienke R and Dutch Prolactinoma Study Group, Dutch Prolactinoma Study Group},
  title = {The Changing Treatment Paradigm for Prolactinoma—A Prospective Series of 100 Consecutive Neurosurgical Cases},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae652}
}
Kostenlos starten →